This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss
For any queries, please contact Customer Services or your Account Manager. Dismiss
News & Analysis (1798)
-
December 10, 2025 | Official Statement Teva removes over 200 improper patent listings under pressure from US FTC
...Court of Appeals for the Federal Circuit decision that affirmed that Teva’s patents were improperly listed...
Sections: Antitrust
-
December 09, 2025 | Insight ‘Settled expectations’ not mandamus-worthy, panel rules in win for USPTO
Sections: Intellectual Property
-
December 09, 2025 | Official Statement Turkish steel rebar producer appeals US CIT's antisubsidy ruling
Sections: Trade
Get the inside track, with MLex
With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
TRY MLEX FREE FOR 14 DAYS
View full search results
Already a subscriber? Click here to login